🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

How do hormones and diet influence the outcome of #cancer therapy?

Wilbert Zwart of the Netherlands Cancer Institute gave an amazing lecture on this topic at #KNCVMCCB2026 covering various strategies to use this information for improved treatments.

https://www.nature.com/articles/s41586-025-09869-0
#DrugDiscovery #Oncology #Fasting #Diet #Hormones

Facing long wait times and high costs for CAR-T cell therapy? Discover why patients are turning to Medical Tourism China for faster access to world-class oncology care (2-6 weeks).

As a medical concierge provider, MedBridgeNZ handles the complex travel, translation, and data logistics—we don't provide medical treatments, but we clear the path to those who do.

Read our 2026 guide here: https://zurl.co/IFera

#CARTtherapy #Oncology #MedicalConcierge #MedicalTourismChina #ChinaMedicalTourism

Navigating CAR-T Cell Therapy Cost in China (2026)

Key TakeawaysKey Takeaways: Accessing CAR-T in China • Accelerated Timelines: Chinese medical infrastructure compresses the vein-to-vein CAR-T wait time to just 2 to 6 weeks, compared to the 3 to 8 months frequently seen in the US and UK systems. • Significant Cost Reduction: The total out-of-pocket expense for commercial CAR-T in China ranges from $150,000 to $200,000, representing a 60% to 70% reduction compared to Western pricing models. • Equivalent Clinical Efficacy: Peer-reviewed data indi

Medbridge Nz
Vaccine Cuts Risk of Common Cancer For Decades, Major Study Finds. Via @sciencealert #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Oncology

Vaccine Cuts Risk of Common Ca...
Vaccine Cuts Risk of Common Cancer For Decades, Major Study Finds

When 12-year-olds receive a letter from the school nurse about the HPV vaccine, their reactions are often mixed.

ScienceAlert
What stage is cancer typically in if it has spread to distant organs?
A) Stage I
B) Stage II
C) Stage III
D) Stage IV
#cancerstages #oncology #metastasis #medicaleducation ... Continue to: https://www.facebook.com/1130092409221646/posts/1280607674170118

Photodynamic Therapy offers a targeted, minimally invasive way to destroy cancer cells using light‑activated medicine.

Discover more on Banish Cancer Blog.

#CancerTreatment #Oncology #BanishCancer

OSM CAR-T is a newly engineered immune-cell therapy designed to specifically target and destroy osteosarcoma, the most common form of bone cancer affecting children and young adults.
#Oncology #Immunology #CellBiology #cancer #sflorg
https://www.sflorg.com/2026/03/ongy03172601.html
Researchers develop promising new therapy for most common form of bone cancer in children and young adults

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children

Cancer Death Rates Fall to Record Low in The #UK 🇬🇧, But Some Types Are Rising. Via @sciencealert #Health ❤️‍🩹 🧑‍⚕️ #MedicalScience 💉💊🏥🩸😷 #Oncology

Cancer Death Rates Fall to Rec...
Cancer Death Rates Fall to Record Low in The UK, But Some Types Are Rising

Good news: cancer death rates in the UK have fallen to their lowest level on record.

ScienceAlert

New clinical trial (phase 3) in metastatic colorectal cancer:

Adding tumor debulking surgery to standard palliative chemotherapy did not significantly improve survival.

Median survival:(382 pts)
• Chemo alone: 27.5 months
• Chemo + surgery: 30 months

👉 Takeaway: Surgery may not add clear survival benefit in patients with multiorgan metastases.

#MedTwitter #Oncology #ColorectalCancer https://jamanetwork.com/journals/jama/fullarticle/2846530 #press

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer

This randomized clinical trial examines whether tumor debulking added to palliative chemotherapy improves survival of patients with multiorgan metastatic colorectal cancer.

New clinical trial (phase 3) in metastatic colorectal cancer:

Adding tumor debulking surgery to standard palliative chemotherapy did not significantly improve survival.

Median survival:(382 pts)
• Chemo alone: 27.5 months
• Chemo + surgery: 30 months

👉 Takeaway: Surgery may not add clear survival benefit in patients with multiorgan metastases.

#MedTwitter #Oncology #ColorectalCancer https://jamanetwork.com/journals/jama/fullarticle/2846530 #press

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer

This randomized clinical trial examines whether tumor debulking added to palliative chemotherapy improves survival of patients with multiorgan metastatic colorectal cancer.